Rwei-Ling Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rwei-Ling Yu has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Hsiang Tan
Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
18 shared publications Chun-Hsiang Tan
Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
5 shared publicationsPi-Shan Sung
Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
5 shared publicationsWei-Pin Hong
Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
5 shared publicationsChia‐Yen Dai
Hepatobiliary Division, Department of Internal Medicine, and Hepatitis Center Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
3 shared publicationsChung-Yao Chien
Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan
3 shared publications
Latest Publications
- 23 September 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 152, 108997
Disease-specific roles of multidimensional apathy in linking cognitive and social functioning across neurodegenerative diseases
- 23 September 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 152, 108997
Disease-specific roles of multidimensional apathy in linking cognitive and social functioning across neurodegenerative diseases
- Open Access
- 30 May 2026
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 149, 152722
Depression as a Potential Moderator of the Sleep–Apathy Association in Parkinson's disease: Exploratory Evidence from Dual-Cohort Moderation Analyses
- 30 May 2026
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 149, 152722
Open AccessDepression as a Potential Moderator of the Sleep–Apathy Association in Parkinson's disease: Exploratory Evidence from Dual-Cohort Moderation Analyses
- 29 April 2026
- Published by Wiley in British Journal of Clinical Psychology
- Vol. 65 (4) , 1128-1141
Therapeutic effectiveness of group psychotherapy incorporating cognitive and goal management training in substance use disorder patients under deferred prosecution
Objectives: This study aimed to evaluate the effectiveness of a structured group psychotherapy program integrating cognitive training (CT) and goal management training (GMT) across neuropsychological, coping and behavioural levels in patients with substance use disorder (SUD) under deferred prosecution. Methods: Utilizing a pre–post design, this study analysed data from 35 patients under deferred prosecution who were enrolled in a compulsory addiction treatment programme consisting of 10‐session group psychotherapy incorporating CT and GMT. Patients were primarily addicted to heroin, methamphetamine or cannabis. Neuropsychological assessments were conducted before and after the intervention, including the Stroop Colour‐Word Test (SCWT) to assess inhibition, the Tower of London‐DX (ToL‐DX) to assess planning and the Wisconsin Card Sorting Test (WCST) to assess cognitive flexibility. Additionally, participants completed the Daily Executive Behaviours Scale and substance use was tracked via urine tests. Results: Significant improvements were observed in the SCWT colour‐word score ( t = −2.78, p = .009, r t = 0.43), ToL‐DX execution time ( t = 2.40, p = .02, r t = 0.38) and rule violation metrics ( Z = −3.34, p < .001, r z = 0.57), as well as WCST perseverative errors ( Z = −3.00, p = .003, r z = 0.51); however, no significant changes were found in self‐reported assessments or urine tests. Conclusions: The combined CT and GMT intervention significantly improved cognitive functions, although it did not lead to a notable reduction in substance use. This approach was associated with measurable improvements in executive functions, while highlighting the limits of short‐term cognitive enhancement in altering substance use behaviour.
- 29 April 2026
- Published by Wiley in British Journal of Clinical Psychology
- Vol. 65 (4) , 1128-1141
Therapeutic effectiveness of group psychotherapy incorporating cognitive and goal management training in substance use disorder patients under deferred prosecution
Objectives: This study aimed to evaluate the effectiveness of a structured group psychotherapy program integrating cognitive training (CT) and goal management training (GMT) across neuropsychological, coping and behavioural levels in patients with substance use disorder (SUD) under deferred prosecution. Methods: Utilizing a pre–post design, this study analysed data from 35 patients under deferred prosecution who were enrolled in a compulsory addiction treatment programme consisting of 10‐session group psychotherapy incorporating CT and GMT. Patients were primarily addicted to heroin, methamphetamine or cannabis. Neuropsychological assessments were conducted before and after the intervention, including the Stroop Colour‐Word Test (SCWT) to assess inhibition, the Tower of London‐DX (ToL‐DX) to assess planning and the Wisconsin Card Sorting Test (WCST) to assess cognitive flexibility. Additionally, participants completed the Daily Executive Behaviours Scale and substance use was tracked via urine tests. Results: Significant improvements were observed in the SCWT colour‐word score ( t = −2.78, p = .009, r t = 0.43), ToL‐DX execution time ( t = 2.40, p = .02, r t = 0.38) and rule violation metrics ( Z = −3.34, p < .001, r z = 0.57), as well as WCST perseverative errors ( Z = −3.00, p = .003, r z = 0.51); however, no significant changes were found in self‐reported assessments or urine tests. Conclusions: The combined CT and GMT intervention significantly improved cognitive functions, although it did not lead to a notable reduction in substance use. This approach was associated with measurable improvements in executive functions, while highlighting the limits of short‐term cognitive enhancement in altering substance use behaviour.
- Open Access
- 27 March 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (4) , e70801
Deciphering the Impact of EPHA1‐AS1 Gene Polymorphism on Social Cognition Deficits in Parkinson's Disease
Aims: Ephrin type‐A receptor 1 (EPHA1) has been identified as a potential contributor to the pathogenesis of Parkinson's disease (PD). The complex interactions between PD symptoms and the EPHA1 protein warrant further exploration. Methods: A cohort of 509 participants, including 362 normal controls (NCs) and 147 PD patients, was included and genotyped for the ephrin type‐A receptor 1‐antisense 1 ( EPHA1‐AS1 ) gene. Overall and emotion‐specific social cognition were assessed using the Reading the Mind in the Eyes Test. The relationship between the EPHA1‐AS1 gene, PD, and social cognition was analyzed using the Mann–Whitney U test, the Quade test, and moderation analysis. Results: Compared to NCs, PD patients showed markedly poorer social cognition, especially in overall and negative emotions, regardless of genotype. The rs2966700 variant significantly affects the positive subscore among all participants ( p = 0.006), with TT carriers performing better. Furthermore, PD was a significant moderator of the association between rs2966700 and the positive subscore ( p = 0.001), with PD patients carrying the C allele performing worse. Conclusions: This study offers new insights into the interaction between the EPHA1‐AS1 gene and PD, thereby enhancing our understanding of its impact on social cognition, particularly in recognizing positive emotions in individuals with PD.
- 27 March 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (4) , e70801
Open AccessDeciphering the Impact of EPHA1‐AS1 Gene Polymorphism on Social Cognition Deficits in Parkinson's Disease
Aims: Ephrin type‐A receptor 1 (EPHA1) has been identified as a potential contributor to the pathogenesis of Parkinson's disease (PD). The complex interactions between PD symptoms and the EPHA1 protein warrant further exploration. Methods: A cohort of 509 participants, including 362 normal controls (NCs) and 147 PD patients, was included and genotyped for the ephrin type‐A receptor 1‐antisense 1 ( EPHA1‐AS1 ) gene. Overall and emotion‐specific social cognition were assessed using the Reading the Mind in the Eyes Test. The relationship between the EPHA1‐AS1 gene, PD, and social cognition was analyzed using the Mann–Whitney U test, the Quade test, and moderation analysis. Results: Compared to NCs, PD patients showed markedly poorer social cognition, especially in overall and negative emotions, regardless of genotype. The rs2966700 variant significantly affects the positive subscore among all participants ( p = 0.006), with TT carriers performing better. Furthermore, PD was a significant moderator of the association between rs2966700 and the positive subscore ( p = 0.001), with PD patients carrying the C allele performing worse. Conclusions: This study offers new insights into the interaction between the EPHA1‐AS1 gene and PD, thereby enhancing our understanding of its impact on social cognition, particularly in recognizing positive emotions in individuals with PD.
- Open Access
- 2 December 2025
- Published by Springer Nature in Humanities and Social Sciences Communications
- Vol. 13 (1)
Decoding apathy in the middle-aged and older adults: the indirect effect of loneliness and the moderating effect of cognitive function on resilience
- 2 December 2025
- Published by Springer Nature in Humanities and Social Sciences Communications
- Vol. 13 (1)
Open AccessDecoding apathy in the middle-aged and older adults: the indirect effect of loneliness and the moderating effect of cognitive function on resilience
- 30 October 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 192, 352-359
The role of motor subtypes in modulating neuropsychiatric and cognitive function in Parkinson's disease: A group-stratified mediation analysis
- 30 October 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 192, 352-359
The role of motor subtypes in modulating neuropsychiatric and cognitive function in Parkinson's disease: A group-stratified mediation analysis
- 23 August 2025
- Published by Springer Nature in Applied Research in Quality of Life
- Vol. 20 (4) , 1759-1782
Using Moderated Mediation Modelling and the Interaction of Person-Affect-Cognition-Execution Model to Explore Relationships between Psychological Distress, Specific Addictive Behaviors, and Quality of Life across Taiwan, Malaysia, Hong Kong, and China
- 23 August 2025
- Published by Springer Nature in Applied Research in Quality of Life
- Vol. 20 (4) , 1759-1782
Using Moderated Mediation Modelling and the Interaction of Person-Affect-Cognition-Execution Model to Explore Relationships between Psychological Distress, Specific Addictive Behaviors, and Quality of Life across Taiwan, Malaysia, Hong Kong, and China
- Open Access
- 11 July 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (10) , 2269-2271
Elevated Levels of Extracellular Vesicle‐Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease
- 11 July 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (10) , 2269-2271
Open AccessElevated Levels of Extracellular Vesicle‐Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease
- Open Access
- 10 July 2025
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 11 (4) , e147
Association of CD33 genetic variants with neurocognitive profiles in chronic viral hepatitis
Background: CD33 has been implicated in the pathogenesis of Alzheimer’s disease primarily through its role in inhibiting the clearance of beta-amyloid (Aβ). However, genetic studies yield mixed results and it is unclear whether the impact of CD33 is specific to Alzheimer’s disease or related to broader neurodegenerative processes. Interestingly, CD33 has also been shown to interact with the hepatitis B (HBV) and C viruses (HCV). Aims: This study aims to investigate the effects of CD33 single-nucleotide polymorphisms (SNPs) on cognitive functions across diverse populations, including healthy controls, individuals with chronic HBV or HCV and those diagnosed with Parkinson’s disease. Method: We genotyped CD33 SNPs in 563 participants using the Affymetrix platform. Participants’ cognitive functions were cross-sectionally assessed using a neuropsychological test battery spanning six domains. Results: Our analysis revealed that CD33 SNP variations had no significant cognitive impact on healthy individuals or Parkinson’s disease patients. However, chronic HBV and HCV patients exhibited significant cognitive differences, particularly in memory, related to CD33 SNP genotypes. Moderation analysis indicated a heightened influence of CD33 SNPs on cognitive functions in chronic HBV and HCV individuals. Our data also suggest that inflammation severity may modulate the cognitive effects in hepatitis patients with specific CD33 SNPs. Conclusions: This study highlights the importance of CD33 SNPs in cognitive outcomes, emphasising their role in the context of chronic viral hepatitis. It contributes to understanding the cognitive profiles influenced by CD33 SNPs and posits CD33’s potential contribution to neurodegenerative disease progression, potentially intensified by HBV/HCV-induced inflammation.
- 10 July 2025
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 11 (4) , e147
Open AccessAssociation of CD33 genetic variants with neurocognitive profiles in chronic viral hepatitis
Background: CD33 has been implicated in the pathogenesis of Alzheimer’s disease primarily through its role in inhibiting the clearance of beta-amyloid (Aβ). However, genetic studies yield mixed results and it is unclear whether the impact of CD33 is specific to Alzheimer’s disease or related to broader neurodegenerative processes. Interestingly, CD33 has also been shown to interact with the hepatitis B (HBV) and C viruses (HCV). Aims: This study aims to investigate the effects of CD33 single-nucleotide polymorphisms (SNPs) on cognitive functions across diverse populations, including healthy controls, individuals with chronic HBV or HCV and those diagnosed with Parkinson’s disease. Method: We genotyped CD33 SNPs in 563 participants using the Affymetrix platform. Participants’ cognitive functions were cross-sectionally assessed using a neuropsychological test battery spanning six domains. Results: Our analysis revealed that CD33 SNP variations had no significant cognitive impact on healthy individuals or Parkinson’s disease patients. However, chronic HBV and HCV patients exhibited significant cognitive differences, particularly in memory, related to CD33 SNP genotypes. Moderation analysis indicated a heightened influence of CD33 SNPs on cognitive functions in chronic HBV and HCV individuals. Our data also suggest that inflammation severity may modulate the cognitive effects in hepatitis patients with specific CD33 SNPs. Conclusions: This study highlights the importance of CD33 SNPs in cognitive outcomes, emphasising their role in the context of chronic viral hepatitis. It contributes to understanding the cognitive profiles influenced by CD33 SNPs and posits CD33’s potential contribution to neurodegenerative disease progression, potentially intensified by HBV/HCV-induced inflammation.
- Open Access
- 7 June 2025
- Published by Elsevier in Social Science & Medicine
- Vol. 381, 118284
Tailoring anxiety assessment for Parkinson's disease: The Chinese Parkinson anxiety scale with cultural and situational anxiety considerations
- 7 June 2025
- Published by Elsevier in Social Science & Medicine
- Vol. 381, 118284
Open AccessTailoring anxiety assessment for Parkinson's disease: The Chinese Parkinson anxiety scale with cultural and situational anxiety considerations